Stimulation of the hypothalamo-pituitary-adrenocortical axis by the central serotonergic pathway: involvement of endogenous corticotropin-releasing hormone but not vasopressin
Détails
ID Serval
serval:BIB_D532D3740F84
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Stimulation of the hypothalamo-pituitary-adrenocortical axis by the central serotonergic pathway: involvement of endogenous corticotropin-releasing hormone but not vasopressin
Périodique
Journal of Endocrinological Investigation
ISSN
0391-4097 (Print)
Statut éditorial
Publié
Date de publication
08/1991
Volume
14
Numéro
7
Pages
551-7
Notes
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Jul-Aug
Research Support, Non-U.S. Gov't --- Old month value: Jul-Aug
Résumé
Many reports indicate that serotonin plays a role in the regulation of the hypothalamo-pituitary-adrenocortical axis. The present study was designed to elucidate whether the activation of the central serotonergic pathway enhances adrenocorticotropin and corticosterone secretion, and if so, whether the CRH and vasopressin neuronal systems could be mediating this effect. Intraperitoneal administration of a low dose of L-5-hydroxytryptophan (an aromatic L-amino acid precursor of serotonin synthesis; 20 mg/kg bw, 30 minutes before the sacrifice) in rats pretreated with pargyline (a brain monoamine oxidase inhibitor, which enhances monoamine activity; 75 mg/Kg bw, 16 hours before the sacrifice) and carbidopa (a peripheral active inhibitor of the decarboxylation of aromatic L-amino acids, which would permit more monoamine precursor to be available to the brain; 50 mg/Kg bw, 90 minutes before the sacrifice) increased ACTH and corticosterone secretion in plasma. Such an effect was partially blocked by metergoline (a serotonin type-1 and-2 receptor blocker; 1 mg/Kg bw, 90 minutes before the sacrifice), but not by spiperone (a serotonin type-2 and dopamine receptor antagonist; 0.5 mg/Kg bw. 90 minutes before the sacrifice). The activation of the central serotonergic system enhanced the CRH content in the median eminence, whereas it decreased the content of this neuropeptide in the medial basal hypothalamus. These effects were fully abolished by metergoline, but not by spiperone pretreatment. The activation of the serotonergic pathway did not influence the vasopressinergic neuronal system. In vitro experiments using hypothalamic-median eminence fragments incubated with serotonin solutions indicate that this monoamine possesses a CRH releasing effect at concentrations of 1 microM or more.(ABSTRACT TRUNCATED AT 250 WORDS)
Mots-clé
5-Hydroxytryptophan/pharmacology
Adrenal Cortex/drug effects/*physiology
Adrenocorticotropic Hormone/blood
Animals
Carbidopa/pharmacology
Corticosterone/blood
Corticotropin-Releasing Hormone/*physiology
Hypothalamus/drug effects/*physiology
Male
Metergoline/pharmacology
Pargyline/pharmacology
Pituitary Gland/drug effects/*physiology
Rats
Rats, Inbred Strains
Serotonin/*physiology
Spiperone/pharmacology
Vasopressins/*physiology
Pubmed
Web of science
Création de la notice
15/02/2008 16:57
Dernière modification de la notice
20/08/2019 15:55